Taro receives FDA approval for Topicort topical spray
HAWTHORNE, N.Y. — Taro Pharmaceutical Industries reported last week that it has received approval from the Food and Drug Administration for its new drug application Topicort (desoximetasone) topical spray, 0.25%.
Topicort topical spray, 0.25% is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older.
According to Taro, the corticosteroid spray market is approximately $100 million in annual sales in the United States.
Taro Pharmaceutical Industries is a multinational, science-based pharmaceutical company. For further information on Taro, visit its website at Taro.com.
Are you a nurse practitioner or physician’s assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.
Study finds relationship between higher vitamin D, lower risk of benign uterine tumors
RESEARCH TRIANGLE PARK, N.C. — Vitamin D significantly reduces women’s risks of developing uterine fibroids, according to a new study.
The study, conducted by the National Institute of Environmental Health Sciences, part of the National Institutes of Health, found that sufficient amounts of vitamin D reduced the risk of uterine fibroids by 32%. Fibroids, also known as uterine leiomyomata, are benign tumors of the uterus that often result in pain and bleeding in premenopausal women and are a leading cause of hysterectomies. Vitamin D can come from food and supplements, but the body also produces it naturally when the skin is exposed to sun.
"It would be wonderful if something as simple and inexpensive as getting some natural sunshine on their skin each day could help women reduce their chance of getting fibroids," NIEHS researcher and lead study author Donna Baird said.
The study included 1,036 women ages 35 years to 49 years living in the Washington metropolitan area between 1996 and 1999. Researchers at the NIEHS, George Washington University and the Medical University of South Carolina screened participants for fibroids using ultrasound and measured vitamin D in their bloodstreams. Those with more than 20 ng of vitamin D per mL of blood were categorized as sufficient, but some experts think greater amounts are needed for good health.
Similasan announces new hires to director team
HIGHLANDS RANCH, Colo. — Similasan North America today annouced the addition of two new team members to join the company at the director level.
Kim Stark has been named the new director of regulatory affairs and quality assurance. Stark comes to the company with over 10 of years of experience in quality assurance and regulation. For the past 5 years Stark was the director, Global Quality and Regulatory Affairs for Nspire Health Inc. Stark has a degree in Chemistry from the University of Colorado as well as a degree in Criminology from Regis University. Stark started last week, Monday, April 8.
Dora Newlin has joined the marketing team as the new director of marketing. She began last Tuesday, April 9. Newlin comes to Similasan by way of Procter & Gamble, where she worked on Cover Girl, and Orange Glo natural cleaning products. Newlin had been working for Launch Pad, LLC for the past several years. Newlin graduated from the University of Colorado, in Journalism and Mass Communications. She also has over 10 years in the industry with proven results managing and leading teams.
Similasan North America is headquartered south of Denver, Colorado. Similasan makes homeopathic products that offer gentle remedies to provide symptomatic relief from ailments of the eyes, ears, nose, nerves, cough & cold, and kids.